Adicet bio, inc. announces closing of $98 million public follow-on offering and exercise in full of the underwriters' option to purchase additional shares

Redwood city, calif. & boston--(business wire)--adicet bio, inc. (nasdaq: acet), a clinical stage biotechnology company discovering and developing allogeneic gamma delta t cell therapies for autoimmune diseases and cancer, today announced the closing of its previously announced underwritten public offering of 32,379,667 shares of its common stock, which includes 5,325,000 shares sold and issued upon the exercise in full by the underwriters of their option to purchase additional shares of common.
ACET Ratings Summary
ACET Quant Ranking